429 results about "Tubercle" patented technology

The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and/or PKG, a stimulator of guanylyl cyclase and/or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity.

The invention discloses a lung tubercle automatic detection method based on a 3D convolutional neural network(CNN). According to the invention, detection is creatively divided into two phases: (1) a candidate lung tubercle detection phase and (2) a false positive lung tubercle screening-out phase. In every phase, a unique 3D CNN is constructed and trained to be suitable for detection and screening-out of lung tubercles. The 3D CNN of the first phase is used to detect candidate lung tubercle positions of suspected lung tubercles preliminarily, and the 3D CNN of the second phase is used to screen out the false positive lung tubercles of the candidate tubercles, and finally, the positions of the tubercles in a whole lung CT image are found. The existence condition of the tubercles in the whole lung CT image is automatically detected, and by comparing with a conventional artificial tubercle detection way, the lung tubercle automatic detection method provided by the invention has advantages of high detection accuracy, strong robustness, high efficiency, short consumed time, and realizing convenient and effective detection of lung tubercles.

The present invention provides a remedy for sarcoidosis, one of systemic granulomatous diseases, and a method for treating sarcoidosis. A remedy for sarcoidosis containing a Propionibacterium acnes-targeting antibiotic such as minocycline hydrochloride and clindamycin as an active component is prepared. Further, sarcoidosis is treated by administering this remedy for sarcoidosis to sarcoidosis patients.

The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.

A turbine/compressor comprises at least one magneto electric device and a drive train coupled to the magneto electric device. At least one rotor blade is coupled to the drive train. The rotor blade has a shaped leading edge with a series of spaced tubercles formed therealong.

The invention belongs to the technical field of protein structure prediction and drug molecule virtual screening, specifically to a method for screening a compound with targeted action on an inactive conformation of a protein kinase. The method provided by the invention comprises a prediction method for the conformation of an active chain section of the protein kinase, wherein a corresponding DFG-out inactive conformation is generated from the DFG-in active conformation of the protein kinase; the method also comprises a selection method of a combined conformation after implementing butt joint of a II type inhibitor, and the selection method is used for selecting small molecules in conformation prediction and virtual screening. The method for screening a compound with targeted action on an inactive conformation of a protein kinase is already calculated and verified in the protein kinases of seven types of known inactive conformations, wherein the success rate is close to 96%. The method provided by the invention is already applied to the prediction of inactive conformation of PknB protein kinase of tubercle bacillus and the virtual screening of a possible II type inhibitor of PknB, and the bacteriostasis of two kinds of small molecules are already found according to bacteriostatic experiments.

The present invention discloses a screening method of a compound for inhibiting mycobacterium tuberculosis. The method comprises the following steps: (1) establishing a screening model adopting tyrosine phosphatase as a target point: adopting genome DNA of tubercle bacillus H37 Rv as a template, adopting a PCR technology to clone tyrosine phosphatase gene, transforming host cells, culturing the transformant to obtain recombinant tyrosine phosphatase from the culture, carrying out enzyme activity analysis, and establishing the screening model adopting tyrosine phosphatase as the target point; and (2) adopting the screening model established in the step (1) to screen a compound providing inhibition activity for the tyrosine phosphatase. With the method of the present invention, the tyrosine phosphatase inhibitor with anti-mycobacterium tuberculosis effect can be rapidly and efficiently screened. In addition, the present invention further discloses a compound screened by using the screening method, and uses of the compound in preparations of drugs for treatments of diseases, wherein the inducement or one of the inducements of the diseases is the tyrosine phosphatase.

The invention discloses a traditional Chinese medicine composition for treating subacute thyroiditis. The composition is a preparation prepared from the following raw materials by weight: 15-30 parts of hedyotis diffusa, 9-15 parts of honeysuckle, 15-30 parts of dandelion, 15-30 parts of Chinese violet, 9-15 parts of root of common peony, 9-15 parts of radix scrophulariae, 9-15 parts of peach kernel, 9-15 parts of baked turtle shell and 15-30 parts of sweet wormwood. According to clinical study on the treatment of subacute thyroiditis, the traditional Chinese medicine composition provided by the invention has total effective rate of 93.34%, which is significantly better than 73.33% of a prednisone group, and can effectively reduce erythrocyte sedimentation rate and CRP of subacute thyroiditis patients, and effectively improve clinical symptoms of the patients; although the cooling time, improvement time of neck pain and regression time of neck tenderness are longer than those of the prednisone group, the goiter or nodule disappearance time shows no obvious difference from those of the prednisone group; relapse rate after drug withdrawal is 3.33%, which is significantly lower than 20% of the prednisone group; and the composition has little adverse reaction, which is significantly lower than that of the prednisone group. The invention also discloses a preparation method of the traditional Chinese medicine composition granules.

The invention relates to application of kelimycin in mycobacterium tuberculosis infection resistance. The application comprises the following main steps: clinical first-line antitubercular drugs isoniazide and rifamycin are used as contrast, and the antimycobacterial activity of kelimycin is detected by adopting an absolute concentration method. The result indicates that the activity of kelimycin on clinically separated mycobacterium tuberculosis including drug-resistance bacteria is remarkably superior to those of the clinical first-line contrast drugs isoniazide and rifamycin, and novel application of kelimycin is expected to be developed in treatment of tubercle bacillus infected diseases.

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention discloses a PCR (Polymerase Chain Reaction) specific primer, a detecting kit and a detecting method of a benign and malignant thyroid nodule associated gene. Sequences of the PCR specific primer of the thyroid nodule benign and malignant associated gene are as shown in SEQ ID NO:1 to SEQ ID NO:54. The benign and malignant thyroid nodule associated gene disclosed by the invention is closely related to pathological indexes of cases of a benign thyroid nodule and a malignant thyroid nodule and can be used as a biomarker for carrying out benign and malignant thyroid nodule classification on a patient suffering from the thyroid nodules, and effective basis can be provided for clinical individual intervention treatment. The PCR specific primer, the detecting kit and the detecting method, disclosed by the invention, are capable of simultaneously detecting multiple benign and malignant thyroid nodule associated genes of multiple samples, and the detecting efficiency and the accuracy can be effectively increased; meanwhile, the cost is reduced, and the operating steps are simplified.

The invention discloses a reagent for detecting tubercle bacillus infection in vitro and a method thereof. The reagent comprises M233 polypeptide represented by SEQ ID No.1; and cytokine released from T cells is detected by contacting the M233 polypeptide or an analog thereof with the T cells of a tubercle bacillus host to determine whether the T cells identify the M233 polypeptide or the analog thereof. The reagent has the advantages of high sensitivity, good specificity, being free from interference of BCG vaccine and non-tuberculosis mycobacteria vaccine, being capable of detecting active pulmonary tuberculosis patients, the patients with dormant infection and healthy persons who contact with mycobacterium nontuberculosis. The reagent and the method are especially applicable to detecting tuberculosis and/or dormant infection thereof for Chinese people.

The invention relates to a pharmaceutical composition for treating Hashimoto's thyroiditis and a preparation method thereof. The pharmaceutical composition is composed of bupleurum, radix curcumae, prunella vulgaris, rhizoma Dioscoreae Nipponicae, thunberg fritillary bulb, radix scrophulariae, edible tulip, astragalus, dark plum and other components, and can be made into granules, capsules, tablets or pills by the conventional pharmaceutical processes. The pharmaceutical composition has the effects of soothing liver-qi stagnation, reducing phlegm, removing stasis, and softening hardness to dissipate stagnation, and applies to patients with Hashimoto's thyroiditis and thyroid nodules. Clinical studies have shown that the pharmaceutical composition can significantly improve the symptoms of Hashimoto's thyroiditis, reduce the thyroid volume and isthmus thickness, and reduce the level of TgAb and TPOAb, and the total effective rate is 97.22%. In addition, for patients with thyroid nodules, nodules can be significantly reduced or even disappeare, no significant adverse reactions are presented in the course of treatment. Experimental studies have shown that the pharmaceutical composition reduces the level of TgAb and TPOAb, and reduces inflammatory infiltration and thyroid follicular damage.

The invention relates to anti-tubercule bacillus recombination protein. It belongs to gene recombination technique field. Its manufacturing includes the following steps: combining antigen the 190-198 polypeptides of the Ag85B-Mpt64 with Mtb8.4; cloning into escherichia coli vector to express; further purifying to gain. It is recorded as Ag85B-Mpt64190-198-Mtb8.4(SEQ.ID.NO.1). The protein can be used as anti tubercule bacillus subunit vaccine.

A method for augmenting the glans penis provides a minimally invasive introduction of injectable biocompatible material, including hyaluronic acid, to increase the girth of the glans penis while maintaining sensation in the penis. The method initially performs preoperative penile inspection of the girth of a penis. A biocompatible material is injected at a 12 o'clock, a 3 o'clock and 9 o'clock injection point relative to the glans penis. Where damage to the dorsal pedicle may occur, the injection points is at a 10'oclock and a 2 o'clock injection point. The biocompatible material is nontoxic and nonimmunogenic. The biocompatible can also be injected below the corona of the glans penis to create a mushroom effect causing nodules and pearls and intradermal injection causes blebs. Then, postoperative compressive dressing is applied to the penis. Then the penis is measured for postoperative changes in penile girth, and postoperative sexual satisfaction is recorded.

The invention relates to Ag85B-ESAT-6 embedded protein vaccine, which is matched with agent MPL-TDM to immunize mouse, to make the IgG2a/IgG1 and IFN- gamma discharge higher then Ag85B-ESAT-6 fusion protein, while later one can generate same protective effect as BCG after infected by bacillus tubercle.

The invention relates to a reagent kit for diagnosing enzyme linked immune spots infected by tubercle bacillus and a method for preparing a specific antigen. The reagent kit comprises a reagent kit body and a detection reagent arranged in the kit body; the detection reagent comprises a positive standard solution, a chromogenic agent, a concentrated detergent and a diluent; the detection reagent also comprises a specific antigen of mycobacterium tuberculosis, a coated INF-gamma resistant antibody and an enzyme label secondary antibody of a vector protein conjugate; the specific antigen of mycobacterium tuberculosis is fusion protein expressed by an ESAT-6 gene and an EIS gene of the mycobacterium tuberculosis; and the INF-gamma resistant antibody is a murine IgG antibody. The method for preparing the specific antigen comprises the following steps: proper tubercle bacillus special antigen ESAT-6 and EIS are combined; and the prepared recombining fusion protein contains main antigenic determinants of two antigens. The recombining fusion protein definitely contains a T cell epitope suitable for the limitation of different HLA, and does not influence results by different groups and different HLA distribution. Clinical tests on tuberculosis patients and healthy people of different groups show that the reagent kit has more excellent specificity and sensitivity than a current similar product.

The invention relates to a fatty-liver-related liver cancer model building method based on knockout mice. The method is characterized in that APOE-/- and LDLR-/- knockout mice including female mice and male mice are selected, the female mice and the male mice are matched in number, and double knockout mice are obtained; a primer is designed, and the genotypes in mice are identified through a PCR (polymerase chain reaction) system; the PCR (polymerase chain reaction) system comprises an ApoE gene identification PCR conditions and LDLR gene identification PCR conditions; the double knockout mice are pregnant, and suckling mice are obtained; streptozotocin is injected to the suckling mice, the suckling mice begin a high-fat diet after ablactation, and finally the suckling mice surfer from liver cancer; it is identified that the suckling mice begin the high-fat diet after ablactation, fatty liver occurs six weeks later, NASH occurs 8-10 weeks later, dysplastic nodule occurs 13-16 weeks later, and the liver cancer occurs 18-24 weeks later. The occurrence rate of the liver cancer is about 100% 24 weeks later. The time when pure-gene APOE-/- and LDLR-/- knockout mice suffer from NASH and HCC due to the high-fat diet is advanced by 24-30 weeks, and the occurrence rate is high.

The invention relates to a composition used for serological diagnosis of tuberculosis, which comprises a combination of a special antigen epitope peptide of tubercle bacillus Mtb16.3 with at least one tubercle bacillus special antigen epitope peptide selected from 38kD, ESAT-6, CFP10andMPT64.

A human rabies vaccine is prepared from the existing rabies vaccine without adjuvant through adsorbing it by the aluminum hydroxide nanoparticles. Its adsorbed capacity is increased by 10-20 time. It can be used for emergency inoculation for preventing rabies as it has the fast release effect.

The invention belongs to the technical field of medical treatment, and in particular relates to a purification method of tubercle bacilipin Arab mannan (LAM) and a tubercle bacillus diagnostic reagent. In the invention, by utilizing the structural differences that the LAM antigen contains three mannose while other impurities (LM, PIM, and the like) only contain one mannose, and the appetency of lectin (such as flat lentils lectin) to three manna branch structures is far higher than two manna and one manna, the LAM antigen purification is carried out by using the lectin to obtain the LAM antigen with the purity of above 95%. The high-purity antigen obtained by purification can form a reagent for LAM antigen detection and can also form a reagent for enriching urine LAM antigen, purifying LAM antibody and detecting the urine LAM antibody.